表紙
市場調查報告書

癌症遺傳基因面板、分析市場 - 潛在的市場規模,預測,分析:2020年∼2024年

Genomic Cancer Panel and Profiling Markets by Cancer and Germline/somatic type with screening potential market size, customized forecasting/analysis, and Executive and Consultant Guides 2020-2024

出版商 Howe Sound Research 商品編碼 944254
出版日期 內容資訊 英文 401 Pages
商品交期: 最快1-2個工作天內
價格
癌症遺傳基因面板、分析市場 - 潛在的市場規模,預測,分析:2020年∼2024年 Genomic Cancer Panel and Profiling Markets by Cancer and Germline/somatic type with screening potential market size, customized forecasting/analysis, and Executive and Consultant Guides 2020-2024
出版日期: 2020年07月02日內容資訊: 英文 401 Pages
簡介

癌症遺傳基因面板、基因的分析,急速改變癌症的診斷和治療。隨著腫瘤醫生每天使用數百種與癌症相關的遺傳基因資訊,市場從專門性的利基轉移到主流。

本報告提供癌症遺傳基因面板、分析市場相關調查分析,市場概要,市場趨勢,最近的開發,主要企業等相關的系統性資訊。

目錄

第1章 簡介與市場定義

第2章 市場概要

  • 動態的市場企業
  • 腫瘤基因組學
  • 癌症管理 vs. 診斷
  • 採用的階段:未來期望
  • 產業結構完成作用

第3章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 儀器與自動化
  • 診斷技術開發

第4章 癌症面板、簡介的最近的開發

  • 最近的開發
    • 開發的重要性
    • 使用方法

第5章 主要企業的簡介

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Almac Diagnostics
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Blueprint Genetics
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Fulgent Genetics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Integrated Diagnostics
  • Janssen Diagnostics
  • Loxo Oncology
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

第6章 全球癌症遺傳基因面板、簡介市場

  • 全球市場概要:各國
  • 全球市場:癌症的各類型 - 概要
  • 全球生殖細胞、體細胞市場 - 概要

第7章 全球癌症遺傳基因面板、簡介市場:癌症的各類型

  • 全面的面板、簡介
  • 乳癌遺傳基因檢驗
  • 大腸癌症遺傳基因檢驗
  • 婦產科癌症遺傳基因檢驗
  • 血液癌症遺傳基因檢驗
  • 前列腺癌症遺傳基因檢驗
  • 肺癌症遺傳基因檢驗
  • 其他癌症遺傳基因檢驗

第8章 全球癌症遺傳基因檢驗市場:生殖細胞、體細胞

  • 全球體細胞市場
  • 全球生殖細胞市場

第9章 潛在的市場機會 (市場規模)

  • 潛在的癌症診察:各國 - 肺癌症,乳癌,大腸癌症
  • 潛在的癌症診察:各國 - 前列腺癌症,其他癌症,全部的癌症
  • 潛在的市場規模:癌症診斷
  • 潛在的市場規模:治療方法的選擇

附錄

目錄

OVERVIEW:

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. And there is a lot of information to be had. But the COVID-19 Pandemic has impacted the market. Find out how in this thorough report.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

"Genomic Cancer Panel and Profiling Markets by Cancer and Germline/somatic type with screening potential market size, customized forecasting/analysis, and Executive and Consultant Guides 2020-2024" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Cancer Panel Market - Strategic Situation Analysis & COVID Update

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. What are Cancer Gene Panels and Profiling?
  • 1.2. The Sequencing Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1. An Historical Look at Clinical Testing

2. Market Overview

  • 2.1. Players in a Dynamic Market
    • 2.1.1. Academic Research Lab
    • 2.1.2. Diagnostic Test Developer
    • 2.1.3. Instrumentation Supplier
    • 2.1.4. Distributor and Reagent Supplier
    • 2.1.5. Independent Testing Lab
    • 2.1.6. Public National/regional lab
    • 2.1.7. Hospital lab
    • 2.1.8. Physician Office Labs
    • 2.1.9. Audit Body
    • 2.1.10. Certification Body
  • 2.2. Oncogenomics
    • 2.2.1. Carcinogenesis
    • 2.2.2. Chromosomes, Genes and Epigenetics
      • 2.2.2.1. Chromosomes
      • 2.2.2.2. Genes
      • 2.2.2.3. Epigenetics
  • 12.3. Cancer Management vs. Diagnosis
    • 2.3.1. The Role of Risk Assessment
    • 2.3.2. Diagnosis
    • 2.3.3. Managing
    • 2.3.4. Monitoring
  • 2.4. Phases of Adoption-Looking into The Future
  • 2.5. Structure of Industry Plays a Part
    • 2.5.1. Hospital Testing Share
    • 2.5.2. Economies of Scale
      • 2.5.2.1. Hospital vs. Central Lab
    • 2.5.3. Physician Office Lab's
    • 2.5.4. Physician's and POCT

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Level of Care
    • 3.1.2. Companion Dx
    • 3.1.3. Immuno-oncology
    • 3.1.4. Liability
    • 3.1.5. Aging Population
  • 3.2. Factors Limiting Growth
    • 3.2.1. State of knowledge
    • 3.2.2. Genetic Blizzard.
    • 3.2.3. Protocol Resistance
    • 3.2.4. Regulation and coverage
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing Fuels a Revolution
    • 3.4.2. Single Cell Genomics Changes the Picture
    • 3.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4. CGES Testing, A Brave New World
    • 3.4.5. Biochips/Giant magneto resistance based assay

4. Cancer Panels & Profiles Recent Developments

  • 4.1. Recent Developments-Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
      • Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
      • MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
      • NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
      • Germline Results Guides Precision Therapy in Advanced Cancer
      • FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
      • ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
      • Labs Reporting Cancer Risk Mutations from Tumor Testing
      • Users Begin Integrating Genomics Data for Clinical Decision Support
      • Fujitsu Improves Efficiency in Cancer Genomic Medicine
      • Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
      • Universal Genetic Testing for All Breast Cancer Patients
      • Exact Sciences buys Genomic Health
      • Multi-Gene Liquid Biopsy Breast Cancer Panel
      • Thrive to Develop Earlier Detection of Multiple Cancer Types
      • New Gene Panel Identifies High Risk Prostate Cancer
      • Guardant Health Liquid Biopsy Test to be Covered by EviCore
      • Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
      • Natera Commercializes Tumor Whole Exome Sequencing from Plasma
      • Inivata Completes £39.8M Series B Funding Round
      • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
      • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
      • Biodesix Acquires Integrated Diagnostics
      • Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx

5. Profiles of Key Players

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Almac Diagnostics
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Blueprint Genetics
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Fulgent Genetics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Integrated Diagnostics
  • Janssen Diagnostics
  • Loxo Oncology
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

6. The Global Market for Cancer Gene Panels and Profiles

  • 6.1. Global Market Overview by Country
    • 6.1.1. Table-Global Market by Country
    • 6.1.2. Chart - Global Market by Country
  • 6.2. Global Market by Cancer Type - Overview
    • 6.2.1. Table-Global Market by Cancer Type
    • 6.2.2. Chart-Global Market by Cancer Type-Base/Final Year Comparison
    • 6.2.3. Chart-Global Market by Cancer Type-Base Year
    • 6.2.4. Chart-Global Market by Cancer Type-Final Year
    • 6.2.5. Chart-Global Market by Cancer Type-Share by Year
    • 6.2.6. Chart-Global Market by Cancer Type-Segment Growth
  • 6.3. Global Market Germline & Somatic - Overview
    • 6.3.1. Table-Global Market Germline & Somatic
    • 6.3.2. Chart-Global Market Germline & Somatic-Base/Final Year Comparison
    • 6.3.3. Chart-Global Market Germline & Somatic-Base Year
    • 6.3.4. Chart-Global Market Germline & Somatic-Final Year
    • 6.3.5. Chart-Global Market Germline & Somatic-Share by Year
    • 6.3.6. Chart-Global Market Germline & Somatic-Segment Growth

7. Global Cancer Gene Panels & Profiles Markets-By Type of Cancer

  • 7.1. Comprehensive Panels & Profiles
    • 7.1.1. Table Comprehensive Testing-by Country
    • 7.1.2. Chart - Comprehensive Testing Growth
  • 7.2. Breast Cancer Gene Testing
    • 7.2.1. Table Breast Cancer Gene Testing-by Country
    • 7.2.2. Chart - Breast Cancer Testing Growth
  • 7.3. Colorectal Cancer Gene Testing
    • 7.3.1. Table Colorectal Cancer Gene Testing-by Country
    • 7.3.2. Chart - Colorectal Cancer Gene Testing Growth
  • 7.4. Gynecological Cancer Gene Testing
    • 7.4.1. Table Gynecological Cancer Gene Testing-by Country
    • 7.4.2. Chart - Gynecological Cancer Gene Testing Growth
  • 7.5. Blood Cancer Gene Testing
    • 7.5.1. Table Blood Cancer Gene Testing-by Country
    • 7.5.2. Chart - Blood Cancer Gene Testing Growth
  • 7.6. Prostate Cancer Gene Testing
    • 7.6.1. Table Prostate Cancer Gene Testing-by Country
    • 7.6.2. Chart - Prostate Cancer Testing Growth
  • 7.7. Lung Cancer Gene Testing
    • 7.7.1. Table Lung Cancer Gene Testing-by Country
    • 7.7.2. Chart - Lung Cancer Gene Testing Growth
  • 7.8. Other Cancer Gene Testing
    • 7.8.1. Table Other Cancer Gene Testing-by Country
    • 7.8.2. Chart - Other Cancer Gene Testing Growth

8. Global Cancer Gene Testing Markets-Germline and Somatic

  • 8.1. Global Market Somatic
    • 8.2.1. Table Somatic-by Country
    • 7.2.2. Chart - Somatic Testing Growth
  • 7.3. Global Market Germline
    • 7.3.1. Table Germline-by Country
    • 7.3.2. Chart - Germline Testing Growth

9. Potential Market Opportunity Sizes

  • 9.1. Potential Cancer Screening by Country: Lung, Breast & Colorectal
  • 9.2. Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 9.3. Potential Market Size - Cancer Diagnosis
  • 9.4. Potential Market Size-Therapy Selection

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. FDA Approved Human Genetic Tests
  • III. Pharmacogenomic Biomarkers in Drug Labeling

Table of Tables

  • Table 1: Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 2: Market Players by Type
  • Table 3: The Base Pairs
  • Table 4: Five Factors Driving Growth
  • Table 5: Four Factors Limiting Growth
  • Table 6: Key Diagnostic Laboratory Technology Trends
  • Table 7: Next Generation Sequencing Technologies - Speed and Cost
  • Table 8: Global Cancer Panel Market by Region
  • Table 9: Global Market by Cancer Type
  • Table 10: Global Market Germline & Somatic
  • Table 11: Comprehensive Testing by Country
  • Table 12: Breast Cancer Gene Testing by Country
  • Table 13: Colorectal Cancer Gene Testing by Country
  • Table 14: Gynecological Cancer Testing by Country
  • Table 15: Blood Cancer Gene Testing by Country
  • Table 16: Prostate Cancer Gene Testing by Country
  • Table 17: Lung Cancer Gene Testing by Country
  • Table 18: Other Cancer Gene Testing by Country
  • Table 19: Somatic by Country
  • Table 20: Germline by Country
  • Table 21: Potential Screening Market: Lung, Breast & Colorectal
  • Table 22: Potential Screening Market: Prostate, Other & All
  • Table 23: Potential Cancer Diagnosis Market Size
  • Table 24: Potential Cancer Management Market Size
  • Table 25: 2020 Laboratory Fee Schedule
  • Table 26: FDA Approved Human Genetic tests
  • Table 27: Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1: VistSeq Hereditary Cancer Panel
  • Figure 2: Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 3: The Genomic Progression of Cancer
  • Figure 4: DNA Strands and Chromosomes
  • Figure 5: Karyogram of Human Chromosomes
  • Figure 6: Size of Various Genomes
  • Figure 7: Germline vs Somatic Mutations
  • Figure 8: Comparing Genomic Diagnostic and Traditional Testing
  • Figure 9: Percentage of World Population Over 65
  • Figure 10: Base Year Country Global Share
  • Figure 11: Global Market by Cancer - Base vs. Final Year
  • Figure 12: Cancer Panel Market Base Year
  • Figure 13: Cancer Panel Market Final Year
  • Figure 14: Cancer Type Share by Year
  • Figure 15: Cancer Type Segment Growth
  • Figure 16: Germline & Somatic - Base vs. Final Year
  • Figure 17: Germline & Somatic Market Base Year
  • Figure 18: Germline & Somatic Market Final Year
  • Figure 19: Germline & Somatic Share by Year
  • Figure 20: Germline & Somatic Segment Growth
  • Figure 21: Comprehensive Testing Growth
  • Figure 22: Breast Cancer Testing Growth
  • Figure 23: Colorectal Cancer Gene Testing Growth
  • Figure 24: Gynecological Cancer Testing Growth
  • Figure 25: Blood Cancer Gene Testing Growth
  • Figure 26: Prostate Cancer Gene Testing Growth
  • Figure 27: Lung Cancer Gene Testing Growth
  • Figure 28: Other Cancer Gene Testing Growth
  • Figure 29: Somatic Testing Growth
  • Figure 30: Germline Testing Growth